142 related articles for article (PubMed ID: 31940465)
21. Latent tuberculosis infection: diagnostic update before introduction of biological drugs.
Martinez-Lopez A; Ruiz-Villaverde R
Eur J Dermatol; 2016 Jun; 26(3):307-8. PubMed ID: 26985763
[No Abstract] [Full Text] [Related]
22. Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents.
So H; Yuen CS; Yip RM
Hong Kong Med J; 2017 Jun; 23(3):246-50. PubMed ID: 28126971
[TBL] [Abstract][Full Text] [Related]
23. Biologic drugs during COVID-19 outbreak.
Montesu MA; Biondi G; Sotgiu G; Sucato F; Satta R
Int J Dermatol; 2020 Oct; 59(10):1293. PubMed ID: 32767379
[No Abstract] [Full Text] [Related]
24. Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China.
Li CR; Mao QX; Chen M; Jia WX; Yao X; Feng SY; Jia H; Gong JQ; Yang XY
Drug Des Devel Ther; 2015; 9():5591-4. PubMed ID: 26508833
[TBL] [Abstract][Full Text] [Related]
25. Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review.
Lee EB; Amin M; Man J; Egeberg A; Wu JJ
J Dermatolog Treat; 2018 Nov; 29(7):671-675. PubMed ID: 29455561
[TBL] [Abstract][Full Text] [Related]
26. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
27. Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases.
Pyo J; Cho SK; Kim D; Sung YK
Korean J Intern Med; 2018 Nov; 33(6):1241-1251. PubMed ID: 29277097
[TBL] [Abstract][Full Text] [Related]
28. Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting.
Kardos M; Kimball AB
J Am Acad Dermatol; 2012 Jan; 66(1):148-52. PubMed ID: 22177633
[TBL] [Abstract][Full Text] [Related]
29. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
[TBL] [Abstract][Full Text] [Related]
30. Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa.
Montaudié H; Seitz-Polski B; Cornille A; Benzaken S; Lacour JP; Passeron T
J Am Acad Dermatol; 2017 Jan; 76(1):156-158. PubMed ID: 27986139
[No Abstract] [Full Text] [Related]
31. Evidenced-based guidelines for tuberculosis screening before biologic treatment initiation.
Shah P; Rebick G; Bajaj S; Desvignes L; Lo Sicco K
J Am Acad Dermatol; 2020 Jul; 83(1):e25-e26. PubMed ID: 32222451
[No Abstract] [Full Text] [Related]
32. Adherence to TNF-alpha inhibitors in patients with hidradenitis suppurativa.
Thomsen SF; Sand FL
J Dermatolog Treat; 2015 Feb; 26(1):97-8. PubMed ID: 24552476
[No Abstract] [Full Text] [Related]
33. Reply to: "Evidence-based guidelines for tuberculosis screening before biologic treatment initiation".
Fernandez AP; Ellis A; Khanna U; Galadari A
J Am Acad Dermatol; 2020 Jul; 83(1):e27-e28. PubMed ID: 32222450
[No Abstract] [Full Text] [Related]
34. QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists.
Baričević D; Popović Grle S; Morović Vergles J; Čuković Čavka S; Jakopović M; Redžepi G; Boras Z; Baričević M; Samaržija M
Acta Clin Croat; 2017 Jun; 56(2):203-209. PubMed ID: 29485786
[TBL] [Abstract][Full Text] [Related]
35. Role for interferon-gamma release assays in latent tuberculosis screening before TNF-α antagonist therapy.
Lioté H; Lioté F
Joint Bone Spine; 2011 Jul; 78(4):352-7. PubMed ID: 21251863
[TBL] [Abstract][Full Text] [Related]
36. Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative?
Brunasso AM; Delfino C; Massone C
Br J Dermatol; 2008 Sep; 159(3):761-3. PubMed ID: 18627370
[No Abstract] [Full Text] [Related]
37. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.
Molinelli E; Diotallevi F; Simonetti O; Brisigotti V; Sapigni C; Radi G; Campanati A; Offidani A
Dermatol Ther; 2020 Nov; 33(6):e14256. PubMed ID: 32860474
[TBL] [Abstract][Full Text] [Related]
38. Successful control of hidradenitis suppurativa with verapamil: a case report.
Laroche ML; Teste M; Vanoost J; Geniaux H
Fundam Clin Pharmacol; 2019 Feb; 33(1):122-124. PubMed ID: 30025186
[TBL] [Abstract][Full Text] [Related]
39. Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure.
Melendez-Gonzalez MDM; Hamad J; Sayed C
J Invest Dermatol; 2021 Dec; 141(12):2975-2979. PubMed ID: 34097922
[No Abstract] [Full Text] [Related]
40. Etanercept for the treatment of hidradenitis suppurativa.
Sotiriou E; Apalla Z; Ioannidos D
Acta Derm Venereol; 2009; 89(1):82-3. PubMed ID: 19197548
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
